Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis

Gastroenterology

Volumn 109, Issue 3, 1995, Pages 850-860

  Mantyh, Christopher R ^a   Vigna, Steven R ^a   Bollinger, R Randall ^a   Mantyh, Patrick W ^b   Maggio, John E ^c   Pappas, Theodore N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUBSTANCE P RECEPTOR;

ARTICLE; CROHN DISEASE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; ULCERATIVE COLITIS;

EID: 0029123521     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(95)90394-1     Document Type: Article

References (60)

1. Differential diagnosis, ulcerative colitis, Crohn's disease and other disorders, including diverticular disease
2. Pathology of inflammatory bowel disease: a critical appraisal in diagnosis and management
3. Pathological mimics of chronic inflammatory bowel disease
4. Overlap in the spectrum of non-specific inflammatory bowel disease—‘colitis indeterminate’
5. Indeterminate colitis in the spectrum of inflammatory bowel disease
6. Differentiation of ulcerative colitis and regional enteritis of colon
7. Outcome of “indeterminant” colitis following ileal pouch-anal anastomosis
8. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis
9. T-cell activation in Crohn's disease
10. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcertaive colitis
11. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa
12. Pathogenetic and clinical relevance of cytokines in inflammatory bowel disease
13. Neutrophil autoantibodies as disease markers for ulcerative colitis
14. Neutrophil autoantibodies in inflammatory bowel disease: are they important?
15. Increased concentrations of interleukin 1-beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease
16. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells
17. Immune activation genes in inflammatory bowel disease
18. Soluble interleukin 2 and CD8 and CD4 receptors in inflammatory bowel disease
19. Prevention of postoperative recurrence
20. Molecular characterization of a functional cDNA for rat substance P receptor
21. Molecular characterization of a functional cDNA encoding the rat substance P receptor
22. Substance P: from extract to excitement
23. Substance P and the inflammatory and immune response
24. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease
25. The rising sun shines on substance P and related peptides
26. Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors
27. Radioimmunoassay of tachykinins
28. Crohn's disease of the colon IV. Clinical features of Crohn's (ileo) colitis
29. Crohn's disease of the large intestine
30. Consequences of ileal pouch-anal anastomosis for Crohn's colitis
31. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease
32. Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process
33. Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression
34. Effects if glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma
35. Selective inhibition of expression of the substance P receptor mRNA in pancreatic acinar AR42J cells by glucocorticoids
36. Substance P as a neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation
37. Flare and itch induced by substance P in human skin
38. Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell dependent
39. Effect of neuropeptides on production of inflammatory cytokines by human monocytes
40. Activation of human neutrophils by substance P: effect on FMLP-stimulated oxidative and arachidonic acid metabolism and on antibody-dependent cell-mediated cytotoxicity
41. Functional neurokinin 1 receptors for substance P are expressed by human vascular endothelium
42. Effect of substance P on the expression of an adhesion moecule ICAM-1 in human vascular endothelial cells
43. Substance P increases neutrophil adhesion to bronchial epithelial cells
44. The role of substance P and calcitonin gene-related peptide in neurogenic plasma extravasation and vasodilatation in the rat
45. Intraneuronal substance P contributes to the severity of experimental arthritis
46. Neuropeptides in the respiratory tract
47. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury
48. Receptors for sensory neuropeptides in human inflammatory diseases: implications for the effector role of sensory neurons
49. The myenteric plexus in regional enteritis: a study of the number of ganglion cells in the ileum in 24 cases
50. The Meissner plexus in Crohn's disease of the colon
51. Crohn's disease: a scanning electron microscopic study
52. Neuroimmune signaling in regulation of intestinal ion transport.
53. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation
54. Alterations in enteric neuron substance P receptors in clostridium difficile toxin A-induced colitis
55. Discovery of CP-96,345 and its characterization in disease models involving substance P
56. Inhibition of neurogenic plasma exudation in guinea-pig airways by CP-96,345, a new non-peptide NK1 receptor antagonist
57. The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation
58. Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P
59. Substance P receptor antagonist blocks granuloma IgM production in vivo
60. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin